REVELATION BIOSCIENCES, INC. (REVB)
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Revelation Biosciences, Inc.
No short interest data available.
Past the 1:250 Nasdaq cap, ineligible for a bid-price compliance period
- 1:7Reverse splitOct 20, 20267 shares → 1
- 1:4Reverse splitJan 28, 20264 shares → 1
- 1:3Reverse splitJul 7, 20253 shares → 1
- 1:16Reverse splitJan 28, 202516 shares → 1
- 1:30Reverse splitJan 25, 202430 shares → 1
- 1:35Reverse splitFeb 1, 202335 shares → 1
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - |
| Cost of Revenue | $27K | $28K | $25K | $40K | $0 | $0 | $0 |
| Gross Profit | -$27K | -$28K | -$25K | -$40K | $0 | $0 | $0 |
| Gross Margin | - | - | - | - | - | - | - |
| Research and Development | $4.06M | $3.55M | $4.15M | $5.38M | $6.91M | $2.56M | $0 |
| Selling, General, and Administrative | $5.01M | $4.43M | $4.51M | $5.49M | $5.04M | $1.23M | $4K |
| Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $9.07M | $7.98M | $8.66M | $10.86M | $11.95M | $3.8M | $4K |
| Operating Income (EBIT) | -$9.07M | -$7.98M | -$8.66M | -$10.86M | -$11.95M | -$3.8M | -$4K |
| Operating Margin | - | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $42K | $0 | $0 |
| Interest Income | $0 | $0 | $0 | $0 | $0 | $11K | $0 |
| Other Income (Expense) | $157K | -$7.06M | $8.54M | $35K | -$36K | $126 | $0 |
| Income Before Tax (EBT) | -$8.91M | -$15.04M | -$120K | -$10.83M | -$11.99M | -$3.8M | -$4K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$8.91M | -$15.04M | -$120K | -$10.83M | -$11.99M | -$1.63M | -$4K |
| Net Income Margin | - | - | - | - | - | - | - |
| Supplementary Data | |||||||
| EPS | -167.65 | -613.76 | -58.87 | -67503.59 | -142800.00 | -63228.83 | -47.04 |
| Diluted EPS | -167.65 | -613.76 | -58.87 | -67503.59 | -142800.00 | -63228.83 | -47.04 |
| Weighted Average OS | 88,686 | 24,501 | 2,041 | 160 | 84 | 26 | 77 |
| EBITDA | -$9.04M | -$7.95M | -$8.63M | -$10.84M | -$11.93M | $0 | -$4K |
| EBITDA Margin | - | - | - | - | - | - | - |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $10.7M | $6.5M | $11.99M | $5.25M | $1.27M | $12K | $0 |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $525K | $0 |
| Cash and Short-Term Investments | $10.7M | $6.5M | $11.99M | $5.25M | $1.27M | $537K | $0 |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $34K | $50K | $101K | $73K | $149K | $0 | $0 |
| Total Current Assets | $10.81M | $6.57M | $12.15M | $5.4M | $1.91M | $651K | $0 |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $740K | $56K | $65K | $90K | $130K | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $73.51M | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $31K | $0 | $0 | $0 | $0 | $0 | $23K |
| Total Long-Term Assets | $771K | $56K | $65K | $90K | $130K | $73.51M | $23K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $11.58M | $6.62M | $12.21M | $5.5M | $2.04M | $74.16M | $23K |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $578K | $784K | $1.36M | $554K | $596K | $0 | $0 |
| Short-Term Debt | $23K | $0 | $0 | $0 | $17K | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $210K | $2K | $3.44M | $2.91M | $0 | $3.43M | $26K |
| Total Current Liabilities | $2M | $1.91M | $5.56M | $4.45M | $2.14M | $3.43M | $26K |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 | $2.91M | $0 |
| Total Long-Term Liabilities | $724K | $0 | $0 | $0 | $0 | $2.91M | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $1 | $0 |
| Total Liabilities | $2.72M | $1.91M | $5.56M | $4.45M | $2.14M | $6.34M | $26K |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $2K | $522 | $265 | $77 | $282 | $73.51M | $0 |
| Retained Earnings | -$49.42M | -$40.51M | -$25.47M | -$25.35M | -$14.52M | -$5.69M | -$4K |
| Comprehensive Income & Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $58.28M | $45.21M | $32.11M | $26.4M | $14.42M | $0 | $0 |
| Total Equity | $8.86M | $4.71M | $6.65M | $1.05M | -$99K | $67.82M | -$4K |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $11.58M | $6.62M | $12.21M | $5.5M | $2.04M | $74.16M | $23K |
| Supplementary Data | |||||||
| Total Debt | $747K | $0 | $0 | $0 | $17K | $0 | $0 |
| Net Debt | -$9.95M | -$6.5M | -$11.99M | -$5.25M | -$1.26M | -$12K | $0 |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$8.91M | -$15.04M | -$120K | -$10.83M | -$11.99M | -$1.63M | -$4K |
| Depreciation & Amortization | $27K | $28K | $25K | $25K | $17K | $3.8M | $0 |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $595K | $169K | $156K | $301K | $471K | $44K | $0 |
| Changes in Working Capital: | |||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$206K | -$576K | $750K | -$666K | -$270K | $0 | $0 |
| Other Working Capital | $200K | -$2.85M | $232K | -$65K | $626K | -$80K | $4K |
| Total Working Capital Change | -$6K | -$3.42M | $982K | -$731K | $356K | -$80K | $4K |
| Other Non-Cash Items | $28K | -$56K | -$8.33M | $15K | $52K | -$2.34M | $0 |
| Net Cash from Operating | -$8.27M | -$18.32M | -$7.29M | -$11.22M | -$11.09M | -$215K | $0 |
| Investing Activities | |||||||
| Capital Expenditures | $0 | -$19K | $0 | $0 | -$132K | $0 | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | -$74.04M | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $525K | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | -$525K | $0 | $0 |
| Net Cash from Investing | $0 | -$19K | $0 | $0 | -$132K | -$74.04M | $0 |
| Financing Activities | |||||||
| Debt Repaid | - | - | - | - | - | - | - |
| Common Stock Issuance | $12.47M | $12.85M | $14.03M | $4.45M | $600K | $74.25M | -$10K |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $0 | $34 | $11.54M | $0 | $0 | $10K |
| Net Cash from Financing | $12.47M | $12.85M | $14.03M | $15.2M | $8M | $74.26M | $0 |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $4.2M | -$5.49M | $6.74M | $3.98M | -$3.22M | $12K | $0 |
| Supplementary Data | |||||||
| Operating Cash Flow | -$8.27M | -$18.32M | -$7.29M | -$11.22M | -$11.09M | -$215K | $0 |
| Capital Expenditure | $0 | -$19K | $0 | $0 | -$132K | $4 | $0 |
| Free Cash Flow | -$8.27M | -$18.34M | -$7.29M | -$11.22M | -$11.22M | -$215K | $0 |
| Cash at Beginning | $6.5M | $11.99M | $5.25M | $1.27M | $4.49M | $0 | $0 |
| Cash at End | $10.7M | $6.5M | $11.99M | $5.25M | $1.27M | $12K | $0 |